HALO vs. EXEL, NVAX, RGEN, RLAY, ADPT, ALLO, FATE, KOD, NBIX, and IBRX
Should you be buying Halozyme Therapeutics stock or one of its competitors? The main competitors of Halozyme Therapeutics include Exelixis (EXEL), Novavax (NVAX), Repligen (RGEN), Relay Therapeutics (RLAY), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Fate Therapeutics (FATE), Kodiak Sciences (KOD), Neurocrine Biosciences (NBIX), and ImmunityBio (IBRX). These companies are all part of the "biological products, except diagnostic" industry.
Halozyme Therapeutics (NASDAQ:HALO) and Exelixis (NASDAQ:EXEL) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, media sentiment, institutional ownership, earnings, profitability, valuation and risk.
Halozyme Therapeutics has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500.
Halozyme Therapeutics has higher earnings, but lower revenue than Exelixis. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.
In the previous week, Exelixis had 4 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 10 mentions for Exelixis and 6 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.18 beat Exelixis' score of 0.76 indicating that Halozyme Therapeutics is being referred to more favorably in the media.
Exelixis received 75 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. However, 69.15% of users gave Halozyme Therapeutics an outperform vote while only 68.12% of users gave Exelixis an outperform vote.
97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 2.4% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 2.9% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Halozyme Therapeutics has a net margin of 36.94% compared to Exelixis' net margin of 11.10%. Halozyme Therapeutics' return on equity of 225.71% beat Exelixis' return on equity.
Halozyme Therapeutics currently has a consensus target price of $53.14, indicating a potential upside of 18.86%. Exelixis has a consensus target price of $26.13, indicating a potential upside of 24.94%. Given Exelixis' higher possible upside, analysts clearly believe Exelixis is more favorable than Halozyme Therapeutics.
Summary
Halozyme Therapeutics beats Exelixis on 11 of the 18 factors compared between the two stocks.
Get Halozyme Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Halozyme Therapeutics Competitors List
Related Companies and Tools
